Bassem Mikhail, MD
Interventional Cardiology · Hannibal, MONPI 1932189735
Payments from drug & device makers
Across 524 payments — averaging $39.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$5K
- Philips North America LLC$4K
- Medtronic$4K
- Abbott$1K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Shockwave Medical, Inc$727
- plus $5K from 32 others
What the payments were for
- Travel & lodging$3,13515%
- Food & beverage$17,38484%
- Education$1391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 44 | $5,083 |
| Philips North America LLC | 39 | $3,981 |
| Medtronic(2 entities) | 93 | $3,854 |
| Abbott | 38 | $1,071 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 67 | $1,061 |
| Shockwave Medical, Inc | 18 | $727 |
| Johnson & Johnson | 36 | $584 |
| Boston Scientific | 16 | $560 |
| Novartis | 33 | $538 |
| E.r. Squibb & Sons, L.L.C. | 27 | $477 |
| Amgen | 23 | $386 |
| AstraZeneca | 10 | $361 |
| Pfizer | 16 | $271 |
| Penumbra, Inc. | 3 | $262 |
| Boehringer Ingelheim | 15 | $259 |
| Bayer | 4 | $149 |
| Biotronik Inc. | 4 | $136 |
| Cardiovascular Systems Inc. | 4 | $135 |
| Actelion Pharmaceuticals US, Inc. | 3 | $133 |
| Merck | 5 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $80 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $66 |
| Edwards Lifesciences | 2 | $59 |
| Inari Medical, Inc. | 1 | $45 |
| Amarin Pharma, Inc. | 3 | $44 |
| Angiodynamics, Inc. | 1 | $35 |
| Cvrx, Inc. | 1 | $30 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $23 |
| ZOLL Circulation Inc | 1 | $23 |
| United Therapeutics Corporation | 1 | $20 |
| Novo Nordisk | 1 | $16 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Cook Medical LLC | 1 | $15 |
| Impulse Dynamics (USA) Inc. | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $13 |
| Janssen Scientific Affairs, LLC | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$4,541
- Lasers$1,605
- IGT D Peripheral$807
- Micra$595
- (5044) MCOT$254
- Resolute$248
- Diamondback Coronary$163
- COBALT DR MRI SURESCAN$143
- ONYX FRONTIER$136
- Cobalt$131
- Visia AF$129
- FARXIGA$125
- Turbo Power$124
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$124
- Trilogy 100$120
- BRILINTA$120
- CDS - MCT/CEM Monitoring$117
- Indigo System$115
- (9520) IGT Devices Undivided$110
- ASSURITY$109
How this compares
$20,658 in reported general payments places this provider in the 60th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 430 | $436,186 |
| EntrestoSacubitril/Valsartan | 121 | $140,429 |
| XareltoRivaroxaban | 114 | $114,776 |
| JardianceEmpagliflozin | 50 | $55,517 |
| FarxigaDapagliflozin Propanediol | 41 | $46,476 |
| Repatha SureclickEvolocumab | 40 | $30,539 |
| BrilintaTicagrelor | 39 | $17,892 |
| Metoprolol Succinate | 557 | $5,603 |
| Atorvastatin Calcium | 497 | $3,989 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 78 | $2,439 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 22 | $2,409 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 242 | $2,178 |
| Metoprolol Tartrate | 472 | $2,135 |
| ClopidogrelClopidogrel Bisulfate | 222 | $1,966 |
| Lisinopril | 322 | $1,765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $271 | $436,186430 claims |
| NovartisEntresto | $538 | $140,429121 claims |
| Johnson & JohnsonXarelto | $584 | $114,776114 claims |
| AstraZenecaFarxiga, Brilinta | $361 | $64,36880 claims |
| Boehringer IngelheimJardiance | $259 | $55,51750 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Hannibal
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$995K
- Jasvindar SinghSaint Louis$993K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.